LearnGlossaryMarketStocksSuperinvestorsSign in

AQST

Aquestive Therapeutics, Inc.

Healthcare · $584M market cap

Verdict

We can't put a fair value on AQST right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth—?
Sales growth-2.1% a year✗
Free cash flow growth—?
Return on invested capital-43.7%✗

Follow AQST

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 3, 2026: no open-market purchases, 1 sale worth $46K and 4 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Korczynski Sherry

Chief Commercial Officer · 2026-09-09

Sold

$46K

Other filings

Boyd Peter E.

Chief People Officer · 2026-09-09

X-InTheMoney

$2K

Korczynski Sherry

Chief Commercial Officer · 2026-09-09

Option exercise

$23K

Barber Daniel

President and CEO · 2026-09-08

X-InTheMoney

$88K

Jung Cassie

Chief Operating Officer · 2026-09-03

X-InTheMoney

$4K

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing…

Drug Manufacturers - Specialty & Generic

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works